Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00635232 · ClinicalTrials.gov registry record · Phase 2
A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension
A Phase 2 study, sponsored by Ligand Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 261
- Enrollment target
NCT00635232: Completed Phase 2 study, sponsored by Ligand Pharmaceuticals.
NCT00635232 is a Phase 2 study that has completed, run by Ligand Pharmaceuticals. The registered enrollment target is 261 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00635232, a Phase 2 study, has completed, sponsored by Ligand Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 261 participants
- Enrollment target
Study Summary
The purpose of this study is to learn which doses of PS433540 should be given to patients with high blood pressure to lower their blood pressure. This study will also examine how safe PS433540 is when taken by patients with high blood pressure. Approximately 720 patients will be evaluated so that about 375 patients will be entered into the treatment phase of the study and be given PS433540.
Interventions
- DRUG placebo
- DRUG irbesartan
- DRUG PS433540
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
What the finished NCT00635232 record still lists
NCT00635232 is an interventional study that assigns participants to a tested intervention. The registered 261 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% higher).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00635232 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00635232 about?
NCT00635232 is a clinical study titled "A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension". The purpose of this study is to learn which doses of PS433540 should be given to patients with high blood pressure to lower their blood pressure. This study will also examine how safe PS433540 is when taken by patients with high blood pressure. Approximately 720 patients will be evaluated so that ab...
What is the current status of trial NCT00635232?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 261 participants. The study started on 2008-03. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00635232?
The interventions under investigation include: placebo (DRUG), irbesartan (DRUG), PS433540 (DRUG).
Who is sponsoring clinical trial NCT00635232?
This trial is sponsored by Ligand Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00635232's enrollment target sits among peer trials
261 210th of 2000 higher than 1,791 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05124912 · 261 participants · NA
REMASTer: REcurrent Brain Metastases After SRS Trial
- NCT06559891 · 261 participants · NA
THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension
- NCT03713268 · 262 participants
Intraoperative OCT Guidance of Intraocular Surgery II
- NCT06074380 · 262 participants · Phase 4
Non Inferiority Trial Investigating Surfactants Administered Via MIST
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia